PMID- 10423609
OWN - NLM
STAT- MEDLINE
DCOM- 20000713
LR  - 20191103
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 4
IP  - 5-6
DP  - 1997 May-Jun
TI  - Quinapril in patients with congestive heart failure: controlled trial versus 
      captopril.
PG  - 181-8
AB  - After two weeks of a wash-out run-in period with placebo, 131 patients with 
      congestive heart failure (New York Heart Association [NYHA] class II to III) and 
      left ventricular ejection fraction </=40% were randomly assigned to a treatment 
      period of 4 weeks with 10 mg quinapril once daily or 12.5 mg captopril twice 
      daily. At the end of this period, doses were titrated to 20 mg quinapril once 
      daily or 25 mg captopril twice daily on the basis of physician judgment if there 
      were no major adverse reactions and if blood pressure was not below 110/70 mm Hg. 
      Clinical symptoms of heart failure were significantly relieved by both drugs at 
      the end of a 12-week treatment period. At the beginning of the study, 23 (35%) of 
      the 65 patients taking quinapril and 27 (41%) of the 66 patients taking captopril 
      were in NYHA functional class III, whereas, at the end of the trial, only 4 (6%) 
      of the patients in the quinapril group and 14 (22%; p < 0.05 versus quinapril) 
      patients in the captopril group were classified as NYHA class III. Both drugs had 
      a positive effect on echocardiographic parameters. There was a statistically 
      significant increase in exercise duration in both treatment groups (quinapril, 
      6.2 +/- 1.8 versus 7.8 +/- 1.9 minutes, p < 0.001; captopril, 5.9 +/- 1.9 versus 
      7.1 +/- 2.3 minutes, p < 0.001). One patient in the quinapril group died suddenly 
      during the study and two patients in the captopril group dropped out of the study 
      due to persistent dry cough. No patient in the quinapril group reported side 
      effects. Three patients in the captopril group suffered from moderate dry cough, 
      one from taste-blindness, and another from unstable angina. The safety of the 
      tested drugs was confirmed by laboratory tests. Quinapril was as effective as 
      captopril in reducing signs and symptoms of heart failure and in improving the 
      left ventricular function and the exercise capacity with few side effects.
FAU - Acanfora, D
AU  - Acanfora D
AD  - Division of Cardiology, Rehabilitation Institute of Campoli del Monte Taburno, 
      Italy.
FAU - Furgi, G
AU  - Furgi G
FAU - Trojano, L
AU  - Trojano L
FAU - Picone, C
AU  - Picone C
FAU - Iannuzzi, G L
AU  - Iannuzzi GL
FAU - Rossi, M
AU  - Rossi M
FAU - Papa, A
AU  - Papa A
FAU - Rengo, C
AU  - Rengo C
FAU - Rengo, F
AU  - Rengo F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Isoquinolines)
RN  - 0 (Tetrahydroisoquinolines)
RN  - 9G64RSX1XD (Captopril)
RN  - RJ84Y44811 (Quinapril)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Body Weight/drug effects
MH  - Captopril/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Echocardiography, Doppler
MH  - Exercise Test
MH  - Female
MH  - Heart Failure/diagnostic imaging/*drug therapy/physiopathology
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Isoquinolines/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Quinapril
MH  - *Tetrahydroisoquinolines
MH  - Ventricular Function, Left/drug effects
EDAT- 1997/05/01 00:00
MHDA- 2000/07/15 11:00
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.1097/00045391-199705000-00004 [doi]
PST - ppublish
SO  - Am J Ther. 1997 May-Jun;4(5-6):181-8. doi: 10.1097/00045391-199705000-00004.